AI Article Synopsis
- The prevalence of mixed-lineage leukemias in kids is around 13.8% for myeloid antigen-positive acute lymphoblastic leukemia (ALL) and 11.1% for lymphoid antigen-positive acute myeloid leukemia (AML).
- Recent studies indicate that aggressive chemotherapy can reduce the risks associated with myeloid lineage in these patients.
- Our research suggests that myeloid antigen presence in pediatric ALL has little impact on clinical outcomes, as a significant portion of these patients received high-risk treatment, leading to outcomes similar to those of myeloid antigen-negative patients.
Article Abstract
The incidence of mixed-lineage leukemias in the pediatric age group was previously reported as 13.8% for myeloid antigen-positive ALL and 11.1% for lymphoid antigen-positive acute myeloid leukemia (AML). Recent studies showed that extensive chemotherapy protocols overcome the risk of myeloid lineage. Our study also supports most of the previous data and we postulate that myeloid antigen expression in pediatric ALL cases has insignificant effect on clinical presentation, relapse rates and survival. Importantly, 54% of myeloid antigen-expressing ALL patients received high-risk treatment protocols for some other reasons and this may also have contributed to similar outcome in these patients to that observed in myeloid antigen-negative ALL patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!